Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) was rising 25% to $0.88 on Friday morning after Roth Capital Markets started coverage on the stock at a “Buy” rating. Joe Pantiginis set the target price of the stock at $3 and cited the company’s commitment to focus on cancer drugs as a reason for the positive rating. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $1.08 in last trading session, and closed at $1.12, trading in the range of $1.07 – $1.17. The stock showed a positive/negative weekly performance of 60.00%.
Stock analysts at Roth Capital upped their price objective on shares of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) to $7.00 in a report issued on Friday, Analyst Ratings Network.com reports. Roth Capital’s price target suggests a potential upside of 48.94% from the stock’s previous close. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares closed at $4.70 on last trade day, by gaining 6.58%. Stock 52 week range is $0.76 – $5.78. Company’s market capitalization is $368.64 billion.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) EVP Dominic Behan sold 33,332 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $6.25, for a total transaction of $208,325.00. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock rose 5.61% and finished the last session at $7.72. The EPS of the stock remained -0.08. Company’s market capitalization is $1.69 billion.
CoreSite Realty Corp (NYSE:COR), a leading provider of secure and reliable data center solutions across eight key North American markets, announced the company will release its fourth-quarter 2013 financial results prior to market open on Thursday, February 13, 2014, to be followed by its quarterly conference call at 12:00 p.m. (Eastern time). CoreSite Realty Corp (NYSE:COR) stock opened at $0.25 in last trading session and closed at $32.88. The 52 week range of the stock is $27.51 – $38.57 and the day range was $32.82 – $33.49.